Methoxsalen
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Methoxsalen
- Methoxsalen: From Photochemotherapy (Original Indication Not Specified) to Localized Pagetoid Reticulosis
Methoxsalen: From Photochemotherapy (Original Indication Not Specified) to Localized Pagetoid Reticulosis
One-Sentence Summary
Methoxsalen is a psoralen (furocoumarin) compound used in PUVA and extracorporeal photopheresis; the evidence pack does not record its originally registered indication in Australia, as the drug is not currently marketed here. The TxGNN model predicts it may be effective for localized pagetoid reticulosis, a rare, localized variant of cutaneous T-cell lymphoma (CTCL). This is currently a mechanism-based extrapolation only — 0 clinical trials and 0 publications in this evidence pack directly support this specific rare subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack — drug not registered in Australia; TFDA/ARTG-equivalent indication text is a documented data gap (DG001/DG002) |
| Predicted New Indication | Localized Pagetoid Reticulosis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 (mechanism-based) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for methoxsalen is not recorded in this evidence pack (flagged as a High-severity data gap, DG002). However, the evidence pack’s repurposing rationale confirms that methoxsalen (8-MOP) is a psoralen that, once photoactivated by UVA light, intercalates into DNA to form photoadducts and induces apoptosis in lymphocytes — particularly T-cells. This is the pharmacological basis of both topical PUVA therapy and extracorporeal photopheresis (ECP).
Localized pagetoid reticulosis is a rare, localized variant of mycosis fungoides (MF), which sits within the CTCL spectrum. PUVA (methoxsalen plus localized UVA irradiation) is an established treatment modality for CTCL/MF more broadly, so mechanistically it is reasonable to expect activity in this related, rarer subtype. This is reinforced by a closely related predicted indication in the same evidence pack — indolent primary cutaneous T-cell lymphoma (rank 2, evidence level L3) — where ECP using methoxsalen is already a recognised standard treatment for CTCL, supported by two publications.
That said, the rationale for pagetoid reticulosis specifically is an indirect extrapolation from the broader CTCL/MF literature rather than direct evidence: no clinical trials or publications for this exact disease term were identified in this evidence pack.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Australia Market Information
Methoxsalen is not currently registered on the Australian Register of Therapeutic Goods (ARTG) — market status is “not marketed” with 0 listed entries.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link to CTCL/MF is plausible and reinforced by an established treatment precedent for the broader disease spectrum, but there is no direct clinical trial or literature evidence for localized pagetoid reticulosis specifically, and the drug is not currently registered in Australia. Combined with blocking safety data gaps (TFDA/ARTG-equivalent warnings and contraindications not yet obtained), the evidence does not yet support proceeding.
To proceed, the following is needed:
- TFDA/ARTG-equivalent product information — warnings and contraindications (Blocking gap, DG001)
- Confirmed original indication and mechanism-of-action documentation for methoxsalen (DG002)
- Direct clinical evidence (case series or trials) specific to localized pagetoid reticulosis, or a formal extrapolation justification from the broader CTCL/MF evidence base
- Regulatory pathway assessment, given the drug is not currently registered in Australia
Note: A related predicted indication in this evidence pack — indolent primary cutaneous T-cell lymphoma (rank 2) — has stronger direct support (2 peer-reviewed publications, evidence level L3, recommendation “Proceed with Guardrails”) and may warrant separate evaluation as a more actionable near-term direction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.